Andrew J. Rech
Andrew J. Rech
Потвърден имейл адрес: upenn.edu - Начална страница
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
C Twyman-Saint Victor, AJ Rech, A Maity, R Rengan, KE Pauken, ...
Nature 520 (7547), 373-377, 2015
Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy
J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ...
Immunity 49 (1), 178-193. e7, 2018
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients
AJ Rech, R Mick, S Martin, A Recio, NA Aqui, DJ Powell Jr, TA Colligon, ...
Science translational medicine 4 (134), 134ra62-134ra62, 2012
Clinical use of anti‐CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells
AJ Rech, RH Vonderheide
Annals of the New York Academy of Sciences 1174 (1), 99-106, 2009
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ...
Cell 183 (3), 818-834. e13, 2020
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic CancerImmune Cytolytic Activity and Subsets of Pancreatic Cancer
D Balli, AJ Rech, BZ Stanger, RH Vonderheide
Clinical Cancer Research 23 (12), 3129-3138, 2017
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
RA Evans, MS Diamond, AJ Rech, T Chao, MW Richardson, JH Lin, ...
JCI insight 1 (14), 2016
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
N Markosyan, J Li, YH Sun, LP Richman, JH Lin, F Yan, L Quinones, ...
The Journal of clinical investigation 129 (9), 3594-3609, 2019
Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade
LP Richman, RH Vonderheide, AJ Rech
Cell systems 9 (4), 375-382. e4, 2019
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ...
Nature medicine 28 (4), 724-734, 2022
Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer
AJ Rech, H Dada, JJ Kotzin, J Henao-Mejia, AJ Minn, ...
Cancer research 78 (15), 4282-4291, 2018
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human CancerAlternative Neopeptides Predict Survival and Immunity
AJ Rech, D Balli, A Mantero, H Ishwaran, KL Nathanson, BZ Stanger, ...
Cancer immunology research 6 (3), 276-287, 2018
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerImmunogenetic Signatures of BRCA1/2 Breast Cancer
AA Kraya, KN Maxwell, B Wubbenhorst, BM Wenz, J Pluta, AJ Rech, ...
Clinical Cancer Research 25 (14), 4363-4374, 2019
Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer
AJ Rech, R Mick, DE Kaplan, KM Chang, SM Domchek, RH Vonderheide
Cancer immunology, immunotherapy 59, 599-607, 2010
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
EL Carpenter, R Mick, AJ Rech, GL Beatty, TA Colligon, MR Rosenfeld, ...
Clinical Cancer Research 15 (13), 4277-4287, 2009
Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency
R Calcedo, S Somanathan, Q Qin, MR Betts, AJ Rech, RH Vonderheide, ...
Proceedings of the National Academy of Sciences 114 (7), 1655-1659, 2017
T-cell transfer therapy targeting mutant KRAS
AJ Rech, RH Vonderheide
N Engl J Med 376, e11, 2017
Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment
AJ Rech, RH Vonderheide
Cancer Discovery 3 (12), 1330-1332, 2013
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
M Barsch, H Salié, AE Schlaak, Z Zhang, M Hess, LS Mayer, C Tauber, ...
Journal of hepatology 77 (2), 397-409, 2022
Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).
AJ Rech, R Mick, A Recio, A DeMichele, CK Tweed, KR Fox, ...
Journal of Clinical Oncology 28 (15_suppl), 2508-2508, 2010
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20